Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:677-682
doi: 10.1161/CIRCULATIONAHA.107.709972
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Slottow, T. L. P.
Right arrow Articles by Waksman, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Slottow, T. L. P.
Right arrow Articles by Waksman, R.
Related Collections
Right arrow Other Stroke Treatment - Medical

(Circulation. 2007;116:677-682.)
© 2007 American Heart Association, Inc.


New Drugs and Technologies

Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on Patent Foramen Ovale Closure Devices

Tina L. Pinto Slottow, MD; Daniel H. Steinberg, MD; Ron Waksman, MD

From the Division of Cardiology, Washington Hospital Center, Washington, DC.

Correspondence to Ron Waksman, MD, Washington Hospital Center, 110 Irving St NW, Suite 4B-1, Washington, DC 20010. E-mail ron.waksman{at}medstar.net

Patent foramen ovales (PFOs) are common congenital cardiac defects that are more prevalent among patients experiencing cryptogenic stroke than among those with strokes of known origin. Medical treatment for these processes is often considered inadequate, and mechanical closure of the PFO is an attractive, albeit controversial, alternative. Although it is plausible that percutaneous PFO closure will reduce the rate of recurrent stroke in these patients, randomized trials examining the efficacy of devices in this setting have not been completed. In 2007, the Food and Drug Administration convened a meeting of the Circulatory System Devices Panel to discuss the necessity of randomized trials, as well as obstacles to trial enrollment and completion.


Key Words: heart septal defects, atrial • stroke • instrumentation




This article has been cited by other articles:


Home page
CirculationHome page
C. Stollberger, B. Schneider, and J. Finsterer
Letter Regarding Article by Hara et al, "Patent Foramen Ovale Closure by Radiofrequency Thermal Coaptation: First Experience in the Porcine Model and Healing Mechanisms Over Time"
Circulation, March 4, 2008; 117(9): e176 - e176.
[Full Text] [PDF]


Home page
JAMAHome page
A. R. Opotowsky, M. J. Landzberg, S. E. Kimmel, and G. D. Webb
Trends in the Use of Percutaneous Closure of Patent Foramen Ovale and Atrial Septal Defect in Adults, 1998-2004
JAMA, February 6, 2008; 299(5): 521 - 522.
[Full Text] [PDF]


Home page
StrokeHome page
A. B. Singhal and E. H. Lo
Advances in Emerging Nondrug Therapies for Acute Stroke 2007
Stroke, February 1, 2008; 39(2): 289 - 291.
[Full Text] [PDF]